Clinical Trial Update: L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating induction therapy with L-DEP regimen plus a PD-1 antibody for Epstein-Barr Virus-positive hemophagocytic lymphohistiocytosis with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• L-DEP Regimen
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: PD-1 Antibody, Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: NOT_YET_RECRUITING